FDA approves Alembic’s allergic conjunctivitis treatment

The FDA has approved an abbreviated new drug application for olopatadine hydrochloride ophthalmic solution 0.1%, Alembic Pharmaceuticals announced in a press release.
The solution is therapeutically equivalent to Patanol ophthalmic solution 0.1% (Novartis), the release said.
It is indicated for the treatment of signs and symptoms of allergic conjunctivitis.

Full Story →